Mirati Therapeutics, Inc. (MRTX) Files Form 4 Insider Buying : Charles M Baum Buys 20,000 Shares

Mirati Therapeutics, Inc. (MRTX): Charles M Baum , CEO of Mirati Therapeutics, Inc. purchased 20,000 shares on Jun 14, 2016. The Insider buying transaction was reported by the company on Jun 14, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.05 per share for a total value of $141,070.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 8, 2016, Ltd. Braslyn (10% owner) purchased 376,902 shares at $9.90 per share price.On Jan 19, 2016, Mark J Gergen (Executive VP, COO) sold 10,000 shares at $25.92 per share price.Also, On May 27, 2015, Jamie Christensen (SVP & Chief Scientific Officer) sold 4,750 shares at $28.07 per share price.

Shares of Mirati Therapeutics (MRTX) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -1.53 points or -15.90% at $8.09 with 12,07,149 shares getting traded. Post opening the session at $9.25, the shares hit an intraday low of $8.09 and an intraday high of $9.41 and the price vacillated in this range throughout the day. The company has a market cap of $161 M and the number of outstanding shares has been calculated to be 1,99,06,776 shares. The 52-week high of Mirati Therapeutics is $52 and the 52-week low is $8.09.

Mirati Therapeutics Money Flow Index Chart

Company has been under the radar of several Street Analysts.Mirati Therapeutics is Downgraded by Jefferies to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jun 6, 2016.Mirati Therapeutics is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 27 from a previous price target of $29 . The Rating was issued on Jun 6, 2016.Mirati Therapeutics is Downgraded by Leerink Partners to Mkt Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Jun 6, 2016.Mirati Therapeutics is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 29 from a previous price target of $41 . The Rating was issued on May 24, 2016.Mirati Therapeutics is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 41 from a previous price target of $45 . The Rating was issued on May 9, 2016.

Leave a Reply

Mirati Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mirati Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.